Imaging with [18F]AlF-NOTA-KCNA3P has previously been shown to reliably stratify tumours responding to immune checkpoint inhibitors from non-responding tumours, measuring tumour-associated Kv1.3-expressing TEM cells responsible for durable immunological memory response to combination therapy in vivo; however, little is known about whether adjuvant therapies that modulate the immune environment will synergise with the effects of PD1 blockade to promote a lasting immunological memory response at the tumour. The gene discussed is KCNA3; the disease is neoplasm.